Medoclav (Amoxicillin, Clavulanic Acid)

Amoxicillin interferes with bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, leading to cell lysis. Clavulanic acid inhibits β‑lactamase enzymes that many bacteria produce to inactivate amoxicillin. By protecting amoxicillin from enzymatic degradation, clavulanic acid broadens the antimicrobial spectrum and restores activity against resistant strains.

The specific dose and infusion rate of Medoclav are determined by the prescribing clinician based on the infection type, severity, patient age, weight, renal function and local antimicrobial guidelines. Healthcare professionals should follow the product label and institutional protocols when calculating the appropriate regimen.

Safety data for Medoclav in pregnancy are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus, and after a careful risk‑benefit assessment by the prescriber. Limited information is available for lactating women; caution is advised and breastfeeding decisions should be made in consultation with a healthcare provider.

To place an order, submit an enquiry on the Medoclav product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Plain amoxicillin is vulnerable to degradation by bacterial β‑lactamases, limiting its effectiveness against resistant strains. Medoclav combines amoxicillin with clavulanic acid, a β‑lactamase inhibitor, which protects amoxicillin and expands coverage to include many β‑lactamase‑producing organisms. This makes Medoclav a broader‑spectrum option for mixed‑flora infections where resistance is a concern.

Medoclav should be stored at 2‑8 °C in a refrigerator. Keep the vial or bag in its original packaging, protect it from light, and do not freeze or shake vigorously. Before administration, allow the product to reach room temperature if required by the label, and inspect for particulate matter or discoloration.

Medoclav is given by intravenous infusion. The solution is diluted in an appropriate compatible fluid and infused over the time period recommended in the prescribing information, typically ranging from 30 minutes to several hours depending on the dose and patient condition. Administration should be performed by qualified healthcare personnel in a clinical setting.

The most serious adverse reactions include severe hypersensitivity such as anaphylaxis, life‑threatening skin reactions like Stevens‑Johnson syndrome or toxic epidermal necrolysis, Clostridioides difficile‑associated colitis, significant hepatic injury, and hematologic abnormalities such as neutropenia. Prompt recognition and discontinuation of therapy are essential if any of these events occur.

Medoclav is contraindicated in patients with a known hypersensitivity to amoxicillin, clavulanic acid, other β‑lactam antibiotics, or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment or a history of severe allergic reactions to penicillins. The drug should be avoided in such patients unless the prescribing clinician determines that benefits outweigh the risks.